Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640627 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen
A Phase 4 study of Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 380
- Enrollment target
- 20
- Study locations
NCT00640627: Completed Phase 4 study of Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00640627 is a Phase 4 study of Osteoarthritis, Knee that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 380 participants, below the 494-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640627, a Phase 4 study of Osteoarthritis, Knee, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 380 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Celecoxib
Study Locations (20)
Florida
- Pfizer Investigational Site - DeLand
- Pfizer Investigational Site - Naples
- Pfizer Investigational Site - Pembroke Pines
- Pfizer Investigational Site - St. Petersburg
California
- Pfizer Investigational Site - Long Beach
- Pfizer Investigational Site - Paramount
- Pfizer Investigational Site - Tustin
Arizona
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Tucson
Colorado
- Pfizer Investigational Site - Colorado Springs
- Pfizer Investigational Site - Wheat Ridge
Georgia
- Pfizer Investigational Site - Woodstock
Kansas
- Pfizer Investigational Site - Overland Park
Louisiana
- Pfizer Investigational Site - New Orleans
Maryland
- Pfizer Investigational Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2003-12 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
What the finished NCT00640627 record still lists
NCT00640627 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 494-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00640627 names 20 study sites across 13 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00640627 about?
NCT00640627 is a clinical study titled "Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen". To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen
What is the current status of trial NCT00640627?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 380 participants. The study started on 2003-12. Estimated completion is 2004-09.
What conditions does trial NCT00640627 study?
This clinical trial studies the following conditions: Osteoarthritis, Knee.
What interventions are being tested in trial NCT00640627?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00640627?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00640627 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00640627's enrollment target sits among peer trials
380 22nd of 112 higher than 90 of 112 other Osteoarthritis, Knee trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Triamcinolone Ketorolac (TriKe) Knee Trial
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
ZYNRELEF for Pain Management in Total Knee Arthroplasty
RECRUITING · Phase 4
-
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
RECRUITING · Phase 4
-
Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis
ACTIVE NOT RECRUITING · Phase 4
-
Corticosteroid Meniscectomy Randomized Trial
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia